Phenotype of Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in Children.

BACKGROUND AND PURPOSE

To determine the clinical phenotypes, relapse timing, treatment responses, and outcomes of children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

METHODS

We collected the demographic, clinical, laboratory, and radiological data of patients aged <18 years who had been diagnosed with MOGAD at Seoul National University Children's Hospital between January 2010 and January 2022; 100 were identified as positive for MOG antibodies, 43 of whom experienced relapse.

RESULTS

The median age at onset was 7 years (range 2-16 years). The median number of relapses was 2 (range 1-8), and patients were followed up for a median of 65 months (range 5-214 months). The first relapse was experienced before 3 months from onset by 15 patients (34.9%). The most-common initial phenotypes were acute disseminated encephalomyelitis (=17, 39.5%) and optic neuritis (ON; =11, 25.6%). The most-common relapse phenotypes were neuromyelitis optica spectrum disorder (=9, 20.9%), relapsing ON (=6, 14.0%), and multiphasic disseminated encephalomyelitis (=6, 14.0%). Many of the patients (=18, 41.9%) were not specifically categorized. A high proportion of these patients had non-acute disseminated encephalomyelitis encephalitis. Atypical phenotypes such as prolonged fever or hemiplegic migraine-like episodes were also noted. Mycophenolate mofetil and cyclic immunoglobulin treatment significantly reduced the annual relapse rates.

CONCLUSIONS

Our 43 pediatric patients with relapsing MOGAD showed a tendency toward early relapse and various relapse phenotypes. The overall prognoses of these patients were good regardless of phenotype or response to second-line immunosuppressant treatment.